Regeneron Pharmaceuticals Inc. (REGN)

295.87
NASDAQ : Health Technology
Prev Close 286.15
Day Low/High 286.68 / 297.64
52 Wk Low/High 271.57 / 442.00
Avg Volume 739.30K
Exchange NASDAQ
Shares Outstanding 107.98M
Market Cap 31.45B
EPS 22.60
P/E Ratio 15.83
Div & Yield N.A. (N.A)

Latest News

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

Regeneron Announces Upcoming Investor Conference Presentation

Regeneron Announces Upcoming Investor Conference Presentation

TARRYTOWN, N.Y.

FDA Approves EYLEA® (aflibercept) Injection Prefilled Syringe

FDA Approves EYLEA® (aflibercept) Injection Prefilled Syringe

TARRYTOWN, N.Y.

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.

Will Gilead Sciences Stock Really Rally 33% From Here?

Will Gilead Sciences Stock Really Rally 33% From Here?

Shares of Gilead Sciences are jumping higher on its increased investment in Galapagos and a new outperform rating from Wells Fargo.

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.

FDA Approves Dupixent® (dupilumab) For Chronic Rhinosinusitis With Nasal Polyposis

FDA Approves Dupixent® (dupilumab) For Chronic Rhinosinusitis With Nasal Polyposis

* First biologic medicine for adults with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP)

2 Well-Known Stocks You Should Consider Shorting This Week

2 Well-Known Stocks You Should Consider Shorting This Week

These bearish bets are showing both technical and quantitative deterioration.

A Biotech Biggie, a Watchmaker and Other Stocks That Look Good Short

REGN, NOMD, LMNR, MOV and HTHT all recently were downgraded by TheStreet's Quant Ratings.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: SCM, UFCS Downgrades: GCO, GIII, JE, KR, MLAB, OCC, PK, REGN, TAIT, WMK Initiations: HMI, PVTL, SMAR Read on to get TheStreet Quant Ratings' detailed report:

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

Regeneron Announces Upcoming Investor Conference Presentation

Regeneron Announces Upcoming Investor Conference Presentation

TARRYTOWN, N.Y.

TheStreet Quant Rating: C+ (Hold)